Induced AA Amyloid in Hamster: On the Amyloid Enhancing Factor and Protein AA-Cross Reacting Components of Intermediate Molecular Weight
In the pathogenesis of AA-amyloidosis serum amyloid protein A (SAA) and the amyloid enhancing factor (AEF) are thought to play essential roles1. SAA is an acute phase reactant produced in hepatocytes stimulated by cytokines released by inflammatory cells2,3. SAA is present in the bloodstream mainly as a part of high density lipoprotein. of its structure, amino acid composition and DNA sequence in several species a great deal is known already. In contrast, it is not known where the AEF is produced or by what cells. Furthermore, its exact chemical nature is unknown. In the experimental murine model AEF has been described as a (glyco-) protein, because of its inactivation by proteolytic enzymes4,5. However, upto now the AEF resists every attempt to ascribe its activity to one specific protein5. Moreover, regarding the molecular size of the AEF, different data are given in the literature, depending on varying research groups and the source of the AEF, ranging from 10,000 to over 400,000 dalton4,5,6,7,8. The suggestion was made that AEF could be a small molecule that is easily complexing with itself or normal tissue components1,8.
KeywordsLiver Homogenate Amyloid Fibril Mesocricetus Auratus Intermediate Molecular Weight Amyloid Enhance Factor
Unable to display preview. Download preview PDF.
- 2.P. R. Hol, F. W. J. J. Snel, and E. Gruys, Hamster SAA-stimulating factor and lymphocyte activating factor are different factors, in: IVth International Symposium of Veterinary Laboratory Diagnosticians, edited by G. H. A. Borst et al, pl32. The Royal Netherlands Veterinary Association, Utrecht (1986)Google Scholar
- 3.K. P. W. J. McAdam, J. Li, J. Knowles, N. T. Foss, C. A. Dinarello, L. J. Rosenwasser, M. J. Selinger, M. M. Kaplan, R. Goodman, P. N. Herbert, L. L. Baussermann, and L. M. Nadler, The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. Ann. N. Y. Acad. Sc. 389:127 (1982)CrossRefGoogle Scholar
- 4.M. A. Axelrad, and R. Kisilevsky, Biological characterization of amyloid enhancing factor, in: Amyloid and Amyloidosis, edited by G. G. Glenner, P. P. Costa, A. F. de Freitas, p 527. Excerpta Medica, Amsterdam (1980)Google Scholar
- 5.M. L. Baltz, D. Caspi, C. R. K. Hind, A. Feinstein, and M. B. Pepys, Isolation and characterization of amyloid enhancing factor (AEF), in: Amyloidosis, edited by G. G. Glenner, E. F. Ossermann, E. P. Benditt, E. Calkins, A. S. Cohen, D. Zucker-Franklin, pll5. Plenum Press, New York (1986)Google Scholar
- 6.P. R. Hol, A. C. J. van Andel, A. M. van Ederen, J. Draaijer, and E. Gruys, Amyloid enhancing factor in hamster, Br. J. Exp. Pathol. 66:689 (1985)Google Scholar
- 7.K. Kedar, I. Keizman, J. Bleiberg, and E. Sohar, Stimulation of murine amyloidosis by a dialyzable product from pre-treated donors, Br. J. Exp. Pathol. 56:244 (1975)Google Scholar
- 8.Th.A. Niewold, P. R. Hol, A. C. J. van Andel, E. T. G. Lutz, and E. Gruys, Enhancement of amyloid induction by amyloid fibril fragments in hamster, Lab. Invest. 56:544 (1987)Google Scholar
- 13.G. Stokes, An improved Congo red method for amyloid, Med. Lab. Sci. 33:79 (1976)Google Scholar
- 15.D. L. Scott, G. Marhaug, and G. Husby, Comparative studies of the high molecular weight amyloid fibril proteins and similar components from normal tissues, Clin. Exp. Immunol. 52: 693 (1983)Google Scholar
- 16.D. L. Scott, A. Husebekk, and G. Husby, Comparison of a reticulin extract of normal tissue and AA-amyloid fibrils. IRCS Med. Sci. 13:378 (1985)Google Scholar
- 17.A. C. J. van Andel, P. R. Hol, J. H. van der Maas, E. T. G. Lutz, H. Krabbendam, and E. Gruys, Reaggregation of bovine amyloid A fibril components to ß-pleated sheet fibrillar structures, in: Amyloidosis, edited by G. G. Glenner, E. F. Ossermann, E. P. Benditt, E. Calkins, A. S. Cohen, and D. Zucker-Franklin, p39. Plenum Press, New York (1986)CrossRefGoogle Scholar